生命医薬化学分野

101  件  
※ 登録方法の違いにより重複して表示されている場合があります。

  1. Yamashita Yasunobu, Itoh Yukihiro, Takada Yuri, Suzuki Takayoshi: アルツハイマー病治療薬としてのエピジェネティック阻害薬(Frontiers in Alzheimer's and Dementia Research　Epigenetic Inhibitors as Alzheimer's Disease Therapeutic Agents) Chemical & Pharmaceutical Bulletin. 2024.07; 72 (7): 630-637. ( 医中誌 )

  2. Iida Tetsuya, Itoh Yukihiro, Takahashi Yukari, Miyake Yuka, Zamani Farzad, Yamashita Yasunobu, Takada Yuri, Akiyama Toshiki, Ibaraki Jun, Okuda Kyoka, Tokuda Yuto, Nishimura Tomoka, Hidaka Koto, Mori Hiiro, Oba Makoto, Suzuki Takayoshi: リジンデメチラーゼ5に対する蛋白質分解標的キメラ(PROTAC)の同定とその神経突起伸展促進活性(Frontiers in Alzheimer's and Dementia Research　Identification of Proteolysis Targeting Chimeras(PROTACs) for Lysine Demethylase 5 and Their Neurite Outgrowth-Promoting Activity) Chemical & Pharmaceutical Bulletin. 2024.07; 72 (7): 638-647. ( 医中誌 )

  3. Identification of a novel histone H2A mono-ubiquitination-inhibiting cell-active small molecule. 2024.06; 105 129759. ( PubMed , DOI )

  4. Nurani Atika, Yamashita Yasunobu, Taki Yuuki, Takada Yuri, Itoh Yukihiro, Suzuki Takayoshi: 機械学習を基盤とした薬物スクリーニングを介したヒストン脱アセチル化酵素8阻害剤の同定(Advanced Medicinal Chemistry in Academia　Identification of a Histone Deacetylase 8 Inhibitor through Drug Screenings Based on Machine Learning) Chemical & Pharmaceutical Bulletin. 2024.02; 72 (2): 173-178. ( 医中誌 )

  5. Design, synthesis, and biological evaluation of phenylcyclopropylamine-entinostat conjugates that selectively target cancer cells. 2024.02; 100 117632. ( PubMed , DOI )

  6. Takada Yuri, Adachi Kyohei, Fujinaga Yuka, Yamashita Yasunobu, Itoh Yukihiro, Suzuki Takayoshi: リジン特異的脱メチル化酵素1阻害剤としてのSNAIL1ペプチドの構造活性相関研究(Advanced Medicinal Chemistry in Academia　A Structure-Activity Relationship Study of SNAIL1 Peptides as Inhibitors of Lysine-Specific Demethylase 1) Chemical & Pharmaceutical Bulletin. 2024.02; 72 (2): 155-160. ( 医中誌 )

  7. Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity. 2024.01; 98 117579. ( PubMed , DOI )

  8. Discrete prefrontal neuronal circuits determine repeated stress-induced behavioral phenotypes in male mice. 2024.01; ( PubMed , DOI )

  9. Epigenetic Inhibitors as Alzheimer's Disease Therapeutic Agents. 2024; 72 (7): 630-637. ( PubMed , DOI )

  10. Identification of a Histone Deacetylase 8 Inhibitor through Drug Screenings Based on Machine Learning. 2024; 72 (2): 173-178. ( PubMed , DOI )

  11. A Structure-Activity Relationship Study of SNAIL1 Peptides as Inhibitors of Lysine-Specific Demethylase 1. 2024; 72 (2): 155-160. ( PubMed , DOI )

  1. Origin of the kinetic HDAC2 ‐selectivity of an HDAC inhibitor 2023.04; 44 (18): 1604-1609. ( PubMed , DOI )

  1. Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates. 2022.10; 13 (10): 1568-1573. ( PubMed , DOI )

  2. Zhe Wei, Hoshina Naomi, Itoh Yukihiro, Tojo Toshifumi, Suzuki Takayoshi, Hase Koji, Takahashi Daisuke: 新規HDAC1選択的阻害薬は炎症性サイトカイン産生阻害により自己免疫性関節炎を軽減する(A Novel HDAC1-Selective Inhibitor Attenuates Autoimmune Arthritis by Inhibiting Inflammatory Cytokine Production) Biological & Pharmaceutical Bulletin. 2022.09; 45 (9): 1364-1372. ( 医中誌 )

  3. Recent progress on small molecules targeting epigenetic complexes. 2022.04; 67 102130. ( PubMed , DOI )

  4. Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC). 2022.03; 58 (29): 4635-4638. ( PubMed , DOI )

  5. A Novel HDAC1-Selective Inhibitor Attenuates Autoimmune Arthritis by Inhibiting Inflammatory Cytokine Production. 2022; 45 (9): 1364-1372. ( PubMed , DOI )

  1. Identification of Potent and Selective Inhibitors of Fat Mass Obesity-Associated Protein Using a Fragment-Merging Approach. 2021.11; 64 (21): 15810-15824. ( PubMed , DOI )

  2. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group. 2021.07; 22 (22): 3158-3163. ( PubMed , DOI )

  3. Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5 C Degraders 2021.02; 16 (10): 1609-1618. ( PubMed , DOI )

  1. Yeong KY, Khaw KY, Takahashi Y, Itoh Y, Murugaiyah V, Suzuki T: Discovery of gamma-mangostin from Garcinia mangostana as a potent and selective natural SIRT2 inhibitor. Bioorganic chemistry. 2020.01; 94 103403. ( PubMed , DOI )

  2. Itoh Yukihiro: 戦略的化学的アプローチに基づいたリシン修飾酵素のモジュレーターに関する創薬研究(Drug Discovery Researches on Modulators of Lysine-Modifying Enzymes Based on Strategic Chemistry Approaches) Chemical & Pharmaceutical Bulletin. 2020.01; 68 (1): 34-45. ( 医中誌 )

  3. Drug discovery researches on modulators of lysine-modifying enzymes based on strategic chemistry approaches 2020; 68 (1): 34-45. ( PubMed , DOI )

  4. Metabolic-Pathway-Oriented Screening Targeting S-Adenosyl- l -methionine Reveals the Epigenetic Remodeling Activities of Naturally Occurring Catechols 2020; 142 (1): 21-26. ( PubMed , DOI )

  1. Itoh Y, Nakashima Y, Tsukamoto S, Kurohara T, Suzuki M, Sakae Y, Oda M, Okamoto Y, Suzuki T: N+-C-H···O Hydrogen bonds in protein-ligand complexes. Scientific reports. 2019.12; 9 (1): 767. ( PubMed , DOI )

  2. Mellini P, Itoh Y, Elboray EE, Tsumoto H, Li Y, Suzuki M, Takahashi Y, Tojo T, Kurohara T, Miyake Y, Miura Y, Kitao Y, Kotoku M, Iida T, Suzuki T: Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "Selectivity Pocket", Substrate-Binding Site, and NAD+-Binding Site. Journal of medicinal chemistry. 2019.06; 62 (12): 5844-5862. ( PubMed , DOI )

  3. Jaikhan P, Buranrat B, Itoh Y, Chotitumnavee J, Kurohara T, Suzuki T: Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors. Bioorganic & medicinal chemistry letters. 2019.05; 29 (10): 1173-1176. ( PubMed , DOI )

  4. Ota Yosuke, Nakamura Arisa, Elboray Elghareeb E., Itoh Yukihiro, Suzuki Takayoshi: 創薬　近年の進歩と将来　5-フルオロウラシルとLSD1阻害薬の複合体のデザイン、合成および生物学的評価(Drug Discovery: Recent Progress and the Future: Design, Synthesis, and Biological Evaluation of a Conjugate of 5-Fluorouracil and an LSD1 Inhibitor) Chemical & Pharmaceutical Bulletin. 2019.03; 67 (3): 192-195. ( 医中誌 )

  5. Miyake Y, Itoh Y, Hatanaka A, Suzuma Y, Suzuki M, Kodama H, Arai Y, Suzuki T: Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy. Bioorganic & medicinal chemistry. 2019.03; 27 (6): 1119-1129. ( PubMed , DOI )

  6. Ota Y, Nakamura A, Elboray EE, Itoh Y, Suzuki T: Design, Synthesis, and Biological Evaluation of a Conjugate of 5-Fluorouracil and an LSD1 Inhibitor. Chemical & pharmaceutical bulletin. 2019; 67 (3): 192-195. ( PubMed , DOI )

  1. Itoh Y: Chemical Protein Degradation Approach and its Application to Epigenetic Targets. Chemical record (New York, N.Y.). 2018.12; 18 (12): 1681-1700. ( PubMed , DOI )

  2. Itoh Y, Suzuki M: Design, synthesis, and biological evaluation of novel ubiquitin-activating enzyme inhibitors. Bioorganic & medicinal chemistry letters. 2018.09; 28 (16): 2723-2727. ( PubMed , DOI )

  3. Tsukamoto S, Sakae Y, Itoh Y, Suzuki T, Okamoto Y: Computational analysis for selectivity of histone deacetylase inhibitor by replica-exchange umbrella sampling molecular dynamics simulations. The Journal of chemical physics. 2018.03; 148 (12): 125102. ( PubMed , DOI )

  4. Ota Y, Miyamura S, Araki M, Itoh Y, Yasuda S, Masuda M, Taniguchi T, Sowa Y, Sakai T, Itami K, Yamaguchi J, Suzuki T: Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors. Bioorganic & medicinal chemistry. 2018.02; 26 (3): 775-785. ( PubMed , DOI )

  5. Kakizawa T, Ota Y, Itoh Y, Suzuki T: Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors. Bioorganic & medicinal chemistry letters. 2018.01; 28 (2): 167-169. ( PubMed , DOI )

  6. Ota Y, Kakizawa T, Itoh Y, Suzuki T: Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures. Molecules (Basel, Switzerland). 2018; 23 (5): ( PubMed , DOI )

  1. Yukihiro Itoh, Keisuke Aihara, Paolo Mellini, Toshifumi Tojo, Yosuke Ota, Hiroki Tsumoto, Viswas Raja Solomon, Peng Zhan, Miki Suzuki, Daisuke Ogasawara, Akira Shigenaga, Tsubasa Inokuma, Hidehiko Nakagawa, Naoki Miyata, Tamio Mizukami, Akira Otaka, Takayoshi Suzuki: Design, synthesis and biological evaluation of SNAIL1 peptide-based lysine specific demethylase 1 inhibitors Peptide Science 2016. 2017.02; 165-166.

  1. Study of Ligand Binding Selectivity of Histone Deacetylases by Replica-Exchange Umbrella Sampling Molecular Dynamics Simulations 2016.02; 110 (3): 544A-545A.

  1. MEDI 150-Design and synthesis of histone deacetylase 6 selective inhibitors 2006.09; 232

  2. Suzuki Takayoshi, Kouketsu Akiyasu, Itoh Yukihiro, Hisakawa Shinya, Nakagawa Hidehiko, Miyata Naoki: P-440 DISCOVERY OF NOVEL HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS International Symposium on the Chemistry of Natural Products. 2006.07; 2006 "P-440". ( DOI )

  1. 山下 泰信, 高田 悠里, 伊藤 幸裕, 鈴木 孝禎: HDAC8選択的阻害薬の創製とPROTACへの応用 MEDCHEM NEWS. 2023.11; 33 (4): 181-186. ( DOI )

  2. 伊藤 幸裕: 【分子標的薬を極める】分子標的薬のこれから　エピジェネティクス制御を作用機序とする分子標的薬 小児内科. 2023.02; 55 (2): 181-183. ( 医中誌 )

  1. 伊藤 幸裕: 速度論的概念に基づく酵素阻害薬の創製研究 上原記念生命科学財団研究報告集. 2019.12; 33 1-4. ( 医中誌 )

  2. Challenges of young chemists to be global 2019; 139 (2): 185-186. ( PubMed , DOI )

  1. 伊藤 幸裕, 鈴木 孝禎: 薬学における生命指向型化学(「薬」創りの新発想)　有機化学の力を借りた「薬」創り 薬学雑誌. 2017.03; 137 (3): 283-292. ( 医中誌 )

  1. 東條 敏史, 伊藤 幸裕, 展 鵬, 太田 庸介, 鈴木 美紀, 内田 周作, 鈴木 孝禎: Click Chemistryを用いたHDAC1/2選択的阻害薬の創製 日本薬学会年会要旨集. 2016.03; 136年会 (2): 125. ( 医中誌 )

  2. 塚本 修一朗, 榮 慶丈, 伊藤 幸裕, 鈴木 孝禎, 岡本 祐幸: 22aPS-113 拡張アンサンブル分子動力学シミュレーションを用いたエピジェネティックな酵素の阻害剤の選択性に関する研究 日本物理学会講演概要集. 2016; 71 3323. ( DOI )

  1. 伊藤 幸裕, 鈴木 孝禎: エピジェネティクスを操る小分子化合物 ファルマシア. 2014; 50 (11): 1107-1111. ( DOI )

  1. 石川 稔, 伊藤 幸裕, 内藤 幹彦, 橋本 祐一: 2-II-24 細胞内レチノイド結合タンパク質の分解を誘導するレチノイン酸連結化合物の創製(一般演題,日本ビタミン学会第62回大会発表要旨) ビタミン. 2010.04; 84 (4): 189.

  1. 伊藤 幸裕, 鈴木 孝禎, 宮田 直樹: HDAC6選択的阻害薬--HDAC6選択的阻害薬の腫瘍細胞に対する効果 (第1土曜特集 がん分子標的治療の最先端) -- (低分子阻害剤) 医学のあゆみ. 2008.01; 224 (1): 71-74.

  1. Mukherjee, A; Yamashita, Y; Maeda, R; Akiyama, T; Endo, K; Takada, Y; Tsumoto, H; Moriyama, Y; Ito, A; Shirai, F; Tachibana, M; Itoh, Y; Suzuki, T: A Novel PROTAC G9a/GLP Degrader that Inhibits, Similar to G9a siRNA, the Migration of MCF-7 Breast-Cancer Cells without Affecting Proliferation JOURNAL OF MEDICINAL CHEMISTRY. 2025.09; 68 (17): 18258-18271. ( PubMed , DOI )

  2. A Deep-Learning-Aided Drug Screening Based on Visualization of a Hidden Layer as Chemical Space 2025.06; ( DOI )

  1. Identification of Proteolysis Targeting Chimeras (PROTACs) for Lysine Demethylase 5 and Their Neurite Outgrowth-Promoting Activity 2024.07; 72 (7): 638-647. ( DOI )

  2. 伊藤幸裕, 高田悠里, 山下泰信, 鈴木孝禎: 創薬モダリティの高度化と次世代動物評価モデル 4.タンパク質間相互作用阻害を標的とした創薬モダリティ 実験医学. 2024; 42 (2):

  1. Discovery of Selective Histone Deacetylase 1 and 2 Inhibitors: Screening of a Focused Library Constructed by Click Chemistry, Kinetic Binding Analysis, and Biological Evaluation 2023.10; 66 (22): 15171-15188. ( PubMed , DOI )

  1. Medicinal Chemistry Research on Targeting Epigenetic Complexes 2022.07; 80 (7): 664-675. ( DOI )

  1. N+-C-H…O Hydrogen Bonds in Protein-Ligand Complexes and their Application to Drug Design 2020.12; 78 (12): 1151-1162. ( DOI )

  2. Metalloprotein-Catalyzed Click Reaction for In Situ Generation of a Potent Inhibitor 2020.04; 10 (10): 5383-5392. ( DOI )

  1. Okuhira K, Shoda T, Omura R, Ohoka N, Hattori T, Shibata N, Demizu Y, Sugihara R, Ichino A, Kawahara H, Itoh Y, Ishikawa M, Hashimoto Y, Kurihara M, Itoh S, Saito H, Naito M: Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules. Molecular pharmacology. 2017.03; 91 (3): 159-166. ( PubMed , DOI )

  2. Mellini P, Itoh Y, Tsumoto H, Li Y, Suzuki M, Tokuda N, Kakizawa T, Miura Y, Takeuchi J, Lahtela-Kakkonen M, Suzuki T: Potent mechanism-based sirtuin-2-selective inhibition by an in situ-generated occupant of the substrate-binding site, "selectivity pocket" and NAD+-binding site. Chemical science. 2017; 8 (9): 6400-6408. ( PubMed , DOI )

  3. Itoh Y, Suzuki T: "Drug" Discovery with the Help of Organic Chemistry. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2017; 137 (3): 283-292. ( PubMed , DOI )

  4. Chemical biology for pharmaceutical sciences (novel ideas for “drug” discovery) 2017; 137 (3): 281-282. ( PubMed , DOI )

  1. Higuchi F, Uchida S, Yamagata H, Abe-Higuchi N, Hobara T, Hara K, Kobayashi A, Shintaku T, Itoh Y, Suzuki T, Watanabe Y: Hippocampal MicroRNA-124 Enhances Chronic Stress Resilience in Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2016.07; 36 (27): 7253-7267. ( PubMed , DOI )

  2. Kakizawa T, Mizukami T, Itoh Y, Hasegawa M, Sasaki R, Suzuki T: Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide. Bioorganic & medicinal chemistry letters. 2016.02; 26 (4): 1193-1195. ( PubMed , DOI )

  3. Itoh Y, Aihara K, Mellini P, Tojo T, Ota Y, Tsumoto H, Solomon VR, Zhan P, Suzuki M, Ogasawara D, Shigenaga A, Inokuma T, Nakagawa H, Miyata N, Mizukami T, Otaka A, Suzuki T: Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators. Journal of medicinal chemistry. 2016.02; 59 (4): 1531-1544. ( PubMed , DOI )

  4. Itoh Y, Suzuki M, Matsui T, Ota Y, Hui Z, Tsubaki K, Suzuki T: False HDAC Inhibition by Aurone Compound. Chemical & pharmaceutical bulletin. 2016; 64 (8): 1124-1128. ( PubMed , DOI )

  5. Miyamura S, Araki M, Ota Y, Itoh Y, Yasuda S, Masuda M, Taniguchi T, Sowa Y, Sakai T, Suzuki T, Itami K, Yamaguchi J: C-H activation enables a rapid structure-activity relationship study of arylcyclopropyl amines for potent and selective LSD1 inhibitors. Organic & biomolecular chemistry. 2016; 14 (36): 8576-8585. ( PubMed , DOI )

  6. Ota Y, Itoh Y, Kaise A, Ohta K, Endo Y, Masuda M, Sowa Y, Sakai T, Suzuki T: Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen. Angewandte Chemie (International ed. in English). 2016; 55 (52): 16115-16118. ( PubMed , DOI )

  7. Molecular technology for controlling epigenetics: Regulation of histone acetylation and methylation by small molecules 2016; 74 (5): 441-452. ( DOI )

  8. 伊藤幸裕, 粟飯原圭佑, MELLINI Paolo, 東條敏史, 太田庸介, 津元裕樹, SOLOMON Viswas Raja, ZHAN Peng, 鈴木美紀, 小笠原大介, 重永章, 猪熊翼, 中川秀彦, 宮田直樹, 水上民夫, 大高章, 鈴木孝禎: ヒドラジン構造を持つペプチド性LSD1阻害薬の創製 メディシナルケミストリーシンポジウム講演要旨集. 2016; 34th

  1. Itoh Y, Sawada H, Suzuki M, Tojo T, Sasaki R, Hasegawa M, Mizukami T, Suzuki T: Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells. ACS medicinal chemistry letters. 2015.06; 6 (6): 665-670. ( PubMed , DOI )

  2. Kakizawa T, Ota Y, Itoh Y, Tsumoto H, Suzuki T: Histone H3 peptide based LSD1-selective inhibitors. Bioorganic & medicinal chemistry letters. 2015.05; 25 (9): 1925-1928. ( PubMed , DOI )

  3. Design, synthesis, and biological activity of N-alkylated analogue of NCL1, a selective inhibitor of lysine-specific demethylase 1 2015.03; 6 (3): 407-412. ( DOI )

  1. Zhan P, Song Y, Itoh Y, Suzuki T, Liu X: Recent advances in the structure-based rational design of TNKSIs. Molecular bioSystems. 2014.11; 10 (11): 2783-2799. ( PubMed , DOI )

  2. Sekizawa H, Amaike K, Itoh Y, Suzuki T, Itami K, Yamaguchi J: Late-Stage C-H Coupling Enables Rapid Identification of HDAC Inhibitors: Synthesis and Evaluation of NCH-31 Analogues. ACS medicinal chemistry letters. 2014.05; 5 (5): 582-586. ( PubMed , DOI )

  3. Tatum PR, Sawada H, Ota Y, Itoh Y, Zhan P, Ieda N, Nakagawa H, Miyata N, Suzuki T: Identification of novel SIRT2-selective inhibitors using a click chemistry approach. Bioorganic & medicinal chemistry letters. 2014.04; 24 (8): 1871-1874. ( PubMed , DOI )

  4. Suzuki T, Muto N, Bando M, Itoh Y, Masaki A, Ri M, Ota Y, Nakagawa H, Iida S, Shirahige K, Miyata N: Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors. ChemMedChem. 2014.03; 9 (3): 657-664. ( PubMed , DOI )

  5. Target-guided synthesis: Medicinal chemistry strategy to allow target enzymes themselves to synthesize their own inhibitors 2014; 72 (6): 702-716. ( DOI )

  6. Itoh Y, Ogasawara D, Ota Y, Mizukami T, Suzuki T: Synthesis, LSD1 Inhibitory Activity, and LSD1 Binding Model of Optically Pure Lysine-PCPA Conjugates. Computational and structural biotechnology journal. 2014; 9 (14): e201402002. ( PubMed , DOI )

  1. Matsuya Y, Kobayashi Y, Uchida S, Itoh Y, Sawada H, Suzuki T, Miyata N, Sugimoto K, Toyooka N: Search for a novel SIRT1 activator: structural modification of SRT1720 and biological evaluation. Bioorganic & medicinal chemistry letters. 2013.09; 23 (17): 4907-4910. ( PubMed , DOI )

  2. Suzuki T, Ozasa H, Itoh Y, Zhan P, Sawada H, Mino K, Walport L, Ohkubo R, Kawamura A, Yonezawa M, Tsukada Y, Tumber A, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Schofield CJ, Miyata N: Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity. Journal of medicinal chemistry. 2013.09; 56 (18): 7222-7231. ( PubMed , DOI )

  3. Ogasawara D, Itoh Y, Tsumoto H, Kakizawa T, Mino K, Fukuhara K, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N, Suzuki T: Lysine-specific demethylase 1-selective inactivators: protein-targeted drug delivery mechanism. Angewandte Chemie (International ed. in English). 2013.08; 52 (33): 8620-8624. ( PubMed , DOI )

  4. Suzuki T, Kasuya Y, Itoh Y, Ota Y, Zhan P, Asamitsu K, Nakagawa H, Okamoto T, Miyata N: Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. PloS one. 2013.07; 8 (7): e68669. ( PubMed , DOI )

  5. Itoh Y, Suzuki T, Miyata N: Small-molecular modulators of cancer-associated epigenetic mechanisms. Molecular bioSystems. 2013.05; 9 (5): 873-896. ( PubMed , DOI )

  1. Suzuki T, Ota Y, Ri M, Bando M, Gotoh A, Itoh Y, Tsumoto H, Tatum PR, Mizukami T, Nakagawa H, Iida S, Ueda R, Shirahige K, Miyata N: Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. Journal of medicinal chemistry. 2012.11; 55 (22): 9562-9575. ( PubMed , DOI )

  2. Itoh Y, Ishikawa M, Kitaguchi R, Okuhira K, Naito M, Hashimoto Y: Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist. Bioorganic & medicinal chemistry letters. 2012.07; 22 (13): 4453-4457. ( PubMed , DOI )

  3. Suzuki T, Khan MN, Sawada H, Imai E, Itoh Y, Yamatsuta K, Tokuda N, Takeuchi J, Seko T, Nakagawa H, Miyata N: Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors. Journal of medicinal chemistry. 2012.06; 55 (12): 5760-5773. ( PubMed , DOI )

  1. Itoh Y, Kitaguchi R, Ishikawa M, Naito M, Hashimoto Y: Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. Bioorganic & medicinal chemistry. 2011.11; 19 (22): 6768-6778. ( PubMed , DOI )

  2. Itoh Y, Ishikawa M, Kitaguchi R, Sato S, Naito M, Hashimoto Y: Development of target protein-selective degradation inducer for protein knockdown. Bioorganic & medicinal chemistry. 2011.05; 19 (10): 3229-3241. ( PubMed , DOI )

  3. Okuhira K, Ohoka N, Sai K, Nishimaki-Mogami T, Itoh Y, Ishikawa M, Hashimoto Y, Naito M: Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS letters. 2011.04; 585 (8): 1147-1152. ( PubMed , DOI )

  1. Hamada S, Suzuki T, Mino K, Koseki K, Oehme F, Flamme I, Ozasa H, Itoh Y, Ogasawara D, Komaarashi H, Kato A, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N: Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. Journal of medicinal chemistry. 2010.08; 53 (15): 5629-5638. ( PubMed , DOI )

  2. Itoh Y, Ishikawa M, Naito M, Hashimoto Y: Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. Journal of the American Chemical Society. 2010.04; 132 (16): 5820-5826. ( PubMed , DOI )

  3. 浜田翔平, 鈴木孝禎, 鈴木孝禎, 伊藤幸裕, 三野光識, 津元裕樹, 中川秀彦, 水上民夫, 宮田直樹: Jumonji Cドメインを含むヒストン脱メチル化酵素阻害薬の創製 日本薬学会年会要旨集. 2010; 130th (2):

  1. Hamada S, Kim TD, Suzuki T, Itoh Y, Tsumoto H, Nakagawa H, Janknecht R, Miyata N: Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors. Bioorganic & medicinal chemistry letters. 2009.05; 19 (10): 2852-2855. ( PubMed , DOI )

  2. 浜田翔平, 鈴木孝禎, 伊藤幸裕, 三野光識, 津元裕樹, 中川秀彦, 水上民夫, 宮田直樹: N-oxalylglycine誘導体の合成及びヒストン脱メチル化酵素JMJD2阻害活性評価 メディシナルケミストリーシンポジウム講演要旨集. 2009; 28th

  1. Suzuki T, Igari S, Hirasawa A, Hata M, Ishiguro M, Fujieda H, Itoh Y, Hirano T, Nakagawa H, Ogura M, Makishima M, Tsujimoto G, Miyata N: Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists. Journal of medicinal chemistry. 2008.12; 51 (23): 7640-7644. ( PubMed , DOI )

  2. Itoh Y, Suzuki T, Miyata N: Isoform-selective histone deacetylase inhibitors. Current pharmaceutical design. 2008.02; 14 (6): 529-544. ( PubMed , DOI )

  1. Itoh Y, Suzuki T, Kouketsu A, Suzuki N, Maeda S, Yoshida M, Nakagawa H, Miyata N: Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. Journal of medicinal chemistry. 2007.11; 50 (22): 5425-5438. ( PubMed , DOI )

  2. Suzuki T, Hisakawa S, Itoh Y, Suzuki N, Takahashi K, Kawahata M, Yamaguchi K, Nakagawa H, Miyata N: Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors. Bioorganic & medicinal chemistry letters. 2007.08; 17 (15): 4208-4212. ( PubMed , DOI )

  3. Suzuki T, Hisakawa S, Itoh Y, Maruyama S, Kurotaki M, Nakagawa H, Miyata N: Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor. Bioorganic & medicinal chemistry letters. 2007.03; 17 (6): 1558-1561. ( PubMed , DOI )

  1. Suzuki T, Kouketsu A, Itoh Y, Hisakawa S, Maeda S, Yoshida M, Nakagawa H, Miyata N: Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. Journal of medicinal chemistry. 2006.08; 49 (16): 4809-4812. ( PubMed , DOI )

このページの先頭へ▲